Unlocking Neuroprotection: Exercise-Induced Muscle Secretome (Myokines) as a Therapeutic Avenue Against Alzheimer’s Disease Pathogenesis
- 10 June 2026
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2) , 100
Abstract
This review critically evaluates exercise-induced myokines as neuroprotective agents against Alzheimer’s disease (AD) and is structured around three thematic sections: (1) mechanistic foundations of myokine neuroprotection, (2) translational barriers to therapeutic development, and (3) a strategic framework for future research. Epidemiological studies associate physical exercise with reduced AD risk (30–45%), yet mechanisms remain incompletely resolved. Preclinical studies demonstrate that exercise-induced myokines (Irisin, BDNF, Cathepsin B) modulate AD pathology by: (1) attenuating amyloid-beta (Aβ)/tau accumulation, (2) suppressing neuroinflammation, and (3) enhancing synaptic plasticity. However, human exercise interventions show conflicting results influenced by APOE genotype, age, and exercise modality. Associative human data suggest that Interleukin-6 (IL-6) exemplifies pleiotropy—affording neuroprotective effects in acute contexts but potentially detrimental effects in states of chronic inflammation. Therapeutic hurdles include blood-brain barrier (BBB) penetration, pleiotropic risks, and patient heterogeneity. Emerging concepts such as combinatorial approaches (nanocarriers, exercise mimetics) and biomarker-driven trials are proposed as hypothetical future strategies; however, these remain unvalidated and require substantial preclinical development before implemented in clinical care. This narrative review is structured around three thematic sections: mechanistic foundations of myokine neuroprotection, translational barriers to therapeutic development, and a strategic framework for future research. The muscle-brain axis represents a compelling but complex therapeutic target. Based on current preclinical and correlational human evidence, future research should prioritize mechanistic rigor, standardized biomarker validation, and clinically viable delivery strategies. Notably, several approaches discussed herein—including nanocarrier delivery systems, exercise mimetics, and combinatorial myokine cocktails—remain speculative and are presented as future research directions rather than established therapeutic interventions.Keywords
This publication has 42 references indexed in Scilit:
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s diseaseNeurological Sciences, 2019
- Roles of myokines in exercise-induced improvement of neuropsychiatric functionPflügers Archiv - European Journal of Physiology, 2019
- Irisin Mediates Effects on Bone and Fat via αV Integrin ReceptorsCell, 2018
- Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE ε4 GenotypeJAMA Neurology, 2017
- Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer’s DiseaseJournal of Neuroimmune Pharmacology, 2016
- Brain metabolic dysfunction at the core of Alzheimer's diseaseBiochemical Pharmacology, 2014
- Effects of Aerobic Exercise on Mild Cognitive ImpairmentArchives of Neurology, 2010
- Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer DiseaseJAMA, 2008
- AMPK and PPARδ Agonists Are Exercise MimeticsCell, 2008